Odyssey Health, Inc. (ODYY) Reports Positive Findings on Phase 1 Clinical Trials of PRV-002 for Concussions
No adverse reactions were reported in any of the healthy subjects enrolled in the Cohort II Phase 1 clinical trial of PRV-002 Company in talks with military training sites for Phase 2 and 3 clinical trials on concussed patients The CDC estimates that approximately 1.6 to 3.8 million sports and recreation-related concussions occur annually, for which there is no FDA-approved treatment The global concussion market size was valued at $6.8 billion in 2019. This value is expected to rise to $8.9 billion by 2027, growing at a CAGR of 3.6% Odyssey Health (OTC: ODYY), a medical company focused on unique,…